MB
Therapeutic Areas
AVEO Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FOTIVDA (tivozanib) | Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC) | Approved |
| Ficlatuzumab | HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 |
| Rilogrotug (AV-380) | Cancer Cachexia | Phase 1/2 |
| AV-203 | Solid Tumor | Pre-clinical |
| AV-353 | Multiple Myeloma | Pre-clinical |
| LR19155 | Solid Tumor | Pre-clinical |
| LR20011 | Solid Tumor | Pre-clinical |
| LR19129 | Solid Tumor | Pre-clinical |